BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Eli Lilly and Company (LLY) and New York City Mayor Michael R. Bloomberg Announce Lilly Agrees to be First Tenant of East River Science Park; Issue Urgent Call for Healthcare Reform that Protects Innovation and Jobs; ImClone Systems Incorporated (IMCL) to Locate Research HQ in New York City; Company Bringing 125 Scientists With Plans to Expand


7/23/2009 10:00:07 AM

INDIANAPOLIS, July 22 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY - News) announced today during a lease signing event that it has become the first tenant of New York City's new Alexandria Center for Science and Technology at East River Science Park, a development that shows tangible evidence that New York is positioning itself to become a hub for biopharmaceutical research. The biotech park -- located adjacent to the NYU Langone Medical Center in Manhattan -- will house ImClone's Research Division including approximately 125 ImClone scientists with plans to add scientists in those areas that support expansion of the ImClone pipeline. The new location enables unprecedented access to academic research organizations in the New York area. This move is consistent with Lilly's transformation into a fully integrated pharmaceutical network (FIPNet) in which it is increasingly collaborating with external organizations and companies to speed innovation to patients. Nearly 20 current FIPNet partners are located in proximity to the new location. ImClone's manufacturing, development and administrative operations will remain based in New Jersey.


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->